Innovating Works

MULTIFUNSOME

Financiado
Anti EGFR Monoclonal Antibody Conjugated Thermoresponsive Liposome for Triple Ne...
Anti EGFR Monoclonal Antibody Conjugated Thermoresponsive Liposome for Triple Negative Breast Cancer Thermo Chemotherapy In Europe, breast cancer is by far the most important cause of cancer death among women. In particular, triple negative breast cancer (TNBC) is an aggressive histological subtype with limited treatment options and associated with... In Europe, breast cancer is by far the most important cause of cancer death among women. In particular, triple negative breast cancer (TNBC) is an aggressive histological subtype with limited treatment options and associated with poorer prognosis than other breast cancer subtypes. MULTIFUNSOME proposes the use of an anti-Epidermal Growth Factor Receptor (EGFR) monoclonal antibody-conjugated thermoresponsive liposome to deliver simultaneously an anticancer drug and superparamagnetic iron oxide nanoparticles (SPIO) to TNBC cells for thermo-chemotherapy. We will investigate: 1) the effect of combining anti-EGFR targeting and magnetic hyperthermia (MH) on TNBC in such thermo-chemotherapy and 2) how chemical-physical properties of the SPIOs and liposomes influence the therapeutic activity of the formulation. By conjugating anti-EGFR monoclonal antibody to a liposomal delivery system for targeting, drug and SPIO internalization into EGFR overexpressing TNBC cells will be greatly enhanced. SPIO co-encapsulation in the drug nano-cargo will induce a thermal dose to the TNBC cells when an alternating magnetic field is applied. MH will make TNBC cells more sensitive to chemotherapy and trigger the release of drugs intracellularly by enhancing the lipid membrane permeability. As a result, the effectiveness of chemotherapy could be synergistically enhanced by the concurrent application of MH and chemotherapy. The core size of SPIO will serve as a design parameter that can be readily manipulated to maximize the heating efficient of the multicore SPIO so as to minimize the necessary iron oxide content and maximize the drug encapsulation efficiency. The fellowship program will include a comprehensive training which will help the fellow to develop a unique multidisciplinary expertise. Furthermore, the project will generate important knowledge, impacts and collaborations in the European Research Area and could potentially address the critical need for a more efficacious TNBC therapy. ver más
31/08/2019
THE CHANCELLOR MAS...
195K€
Duración del proyecto: 41 meses Fecha Inicio: 2016-03-01
Fecha Fin: 2019-08-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2019-08-31
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
MSCA-IF-2015-EF: Marie Skłodowska-Curie Individual Fellowships (IF-EF)
Cerrada hace 9 años
Presupuesto El presupuesto total del proyecto asciende a 195K€
Líder del proyecto
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5